These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35904479)

  • 1. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
    Lee YG; Guruprasad P; Ghilardi G; Pajarillo R; Sauter CT; Patel R; Ballard HJ; Hong SJ; Chun I; Yang N; Amelsberg KV; Cummins KD; Svoboda J; Gill S; Chong EA; North K; Church SE; Fraietta JA; Chang WJ; Lacey SF; Lu XM; Zhang Y; Whig K; Schultz DC; Cherry S; Gerson J; Schuster SJ; Porazzi P; Ruella M
    Cancer Discov; 2022 Oct; 12(10):2372-2391. PubMed ID: 35904479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics.
    Korell F; Olson ML; Salas-Benito D; Leick MB; Larson RC; Bouffard A; Silva H; Gasparetto A; Berger TR; Kann MC; Mergen M; Kienka T; Wehrli M; Haradhvala NJ; Bailey SR; Letai A; Maus MV
    Sci Transl Med; 2024 Jun; 16(750):eadk7640. PubMed ID: 38838132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells.
    Yang M; Wang L; Ni M; Neuber B; Wang S; Gong W; Sauer T; Sellner L; Schubert ML; Hückelhoven-Krauss A; Hong J; Zhu L; Kleist C; Eckstein V; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Front Immunol; 2020; 11():608167. PubMed ID: 33362794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining T-cell-based immunotherapy with venetoclax elicits synergistic cytotoxicity to B-cell lines in vitro.
    Murakami S; Suzuki S; Hanamura I; Yoshikawa K; Ueda R; Seto M; Takami A
    Hematol Oncol; 2020 Dec; 38(5):705-714. PubMed ID: 32822067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 6. Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.
    O'Steen S; Green DJ; Gopal AK; Orozco JJ; Kenoyer AL; Lin Y; Wilbur DS; Hamlin DK; Fisher DR; Hylarides MD; Gooley TA; Waltman A; Till BG; Press OW
    Cancer Res; 2017 Jul; 77(14):3885-3893. PubMed ID: 28566329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research Progress of Oral BCL-2 Inhibitor Venetoclax in the Treatment of Non-Hodgkin's Lymphoma --Review].
    Guo MQ; Luo XY; Wu HY; Huang YX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1622-1626. PubMed ID: 36208277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect of chimeric antigen receptor modified with Bcl-2 on enhanced solid tumour targeting.
    Wang X; Liu G; Huan T; Wang Y; Jiang B; Liu W; Dai A; Zhang X; Yu F
    Hum Cell; 2024 Sep; 37(5):1421-1433. PubMed ID: 38878230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
    Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
    Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
    Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
    Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor.
    Zhang R; Deng Q; Jiang YY; Zhu HB; Wang J; Zhao MF
    Oncol Rep; 2019 Jun; 41(6):3455-3463. PubMed ID: 30942469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
    Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC
    Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor.
    Wang X; Liu G; Shi X; Wang Y; Jiang B; Liu W; Dai A; Zhang X; Yu F
    Hum Cell; 2024 Jul; 37(4):1107-1119. PubMed ID: 38691335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax Induces BCL-2-Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti-PD-1 Checkpoint Blockade.
    Liao R; Hsu JY; Aboelella NS; McKeever JA; Thomas-Toth AT; Koh AS; LaBelle JL
    Cancer Immunol Res; 2024 Aug; 12(8):1074-1089. PubMed ID: 38810242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.
    Melchor J; Garcia-Lacarte M; Grijalba SC; Arnaiz-Leché A; Pascual M; Panizo C; Blanco O; Segura V; Novo FJ; Valero JG; Pérez-Galán P; Martinez-Climent JA; Roa S
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36854569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
    Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
    Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy.
    Liu J; Li S; Wang Q; Feng Y; Xing H; Yang X; Guo Y; Guo Y; Sun H; Liu X; Yang S; Mei Z; Zhu Y; Cheng Z; Chen S; Xu M; Zhang W; Wan N; Wang J; Ma Y; Zhang S; Luan X; Xu A; Li L; Wang H; Yang X; Hong Y; Xue H; Yuan X; Hu N; Song X; Wang Z; Liu X; Wang L; Liu Y
    Blood; 2024 May; 143(18):1825-1836. PubMed ID: 38211332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
    Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.